DVAX - Dynavax Technologies Corp.
(NaN%)
Sell
Moderate Growth but Declining●Earnings/Profit is Negative
47%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 24.76%
Operating Income is Negative but improving
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -20.39%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 11.93
Debt Ratio is 0.44
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations Growth is 12.96%
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Dynavax Technologies Corp. (DVAX) - www.dynavax.com
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Ryan Spencer
Employees - 351
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.